Clinical outcome of beta3 agonists, Mirabegron and Vibegron sequential therapy for overactive bladder(OAB)
Not Applicable
- Conditions
- Overactive bladder
- Registration Number
- JPRN-UMIN000038636
- Lead Sponsor
- Jikei University school of medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1) Urgency due to bladder infection,urinary malignancies 2) patients who is not available for beta3 agonist treatment 3) deny attending this clinical research
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Beta-3 adrenergic receptor agonists mechanism action detrusor muscle relaxation OAB treatment
Comparative effectiveness beta-3 agonists versus anticholinergics OAB treatment persistence tolerability
Biomarkers predicting treatment response beta-3 agonists Mirabegron Vibegron overactive bladder patients
Cardiovascular safety profile beta-3 agonists Mirabegron Vibegron OAB management strategies
Clinical outcomes sequential switching beta-3 agonists Mirabegron Vibegron OAB refractory patients